Company Information

Upcoming EventsMore >>
Corporate Profile

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix’s highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports.  Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancMore >>

Recent NewsMore >>
02/19/11Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits
SAN DIEGO, Calif., Feb. 19, 2011 /PRNewswire via COMTEX/ --Genoptix, Inc. (Nasdaq: GXDX) announced today that it has entered into a memorandum of understanding ("MOU") providing for the settlement of the putative class action lawsuits currently pending in the Superior Court of the State of California, San Diego County (the "Court") - captioned (1) Page v. Genoptix, Inc., Case No. 37-2011-00050762-CU-BT-NC, (2) Schwitters v. Genoptix, Inc., Case No. 37-2011-00050783-CU-BT-NC and (3) The George Le... 
Printer Friendly Version
02/07/11FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act
SAN DIEGO, Feb. 7, 2011 /PRNewswire via COMTEX/ --Genoptix, Inc. (Nasdaq: GXDX) announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") applicable to the cash tender offer by Novartis to purchase all outstanding shares of common stock of Genoptix at USD$25.00 per share. The termination of the HSR Act waiting period satisfies one of the conditions necessary... 
Printer Friendly Version
01/24/11Genoptix Announces Agreement to be Acquired by Novartis
SAN DIEGO, Jan. 24, 2011 /PRNewswire via COMTEX/ --Genoptix, Inc. (Nasdaq: GXDX) announced today that it has entered into a definitive merger agreement to be acquired by Novartis. Under the terms of the merger agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at USD$25.00 per share. The transaction implies, on a fully-diluted basis, a total equity value of approximately USD$470 million and an enterprise value of USD$330 million. ... 
Printer Friendly Version

There are currently no upcoming events.

Stock Quote
GXDX (Common Stock)
Previous Close$24.99
Change (%) Stock is Up 0.01 (0.04%)
Data as of 03/07/11 9:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Contact Investor Relations:
Marcy Graham
Executive Director, Investor Relations
Genoptix, Inc.
1811 Aston Ave
Carlsbad, CA 92008

E-mail Alerts
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.